Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines

// Kamila Kloudová 1, 3 , Hana Hromádková 1 , Simona Partlová 1, 3 , Tomáš Brtnický 2 , Lukáš Rob 2 , Jiřina Bartůňková 1 , Michal Hensler 3 , Michael J. Halaška 2 , Radek Špíšek 1, 3 , Anna Fialová 1, 3 1 Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic 2 Department of Obstetrics and Gynaecology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic 3 Research Department, Sotio, Prague, Czech Republic Correspondence to: Anna Fialová, email: askallova@centrum.cz Keywords: high-grade serous epithelial ovarian cancer, tumor-associated antigens, immunotherapy, cancer cell lines Received: January 13, 2016      Accepted: May 26, 2016      Published: June 14, 2016 ABSTRACT In order to select a suitable combination of cancer cell lines as an appropriate source of antigens for dendritic cell-based immunotherapy of ovarian cancer, we analyzed the expression level of 21 tumor associated antigens (BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1) in 4 established ovarian cancer cell lines and in primary tumor cells isolated from the high-grade serous epithelial ovarian cancer tissue. More than 90% of tumor samples expressed very high levels of CA125, FOLR1, EPCAM and MUC-1 and elevated levels of Her-2/neu, similarly to OVCAR-3 cell line. The combination of OV-90 and OVCAR-3 cell lines showed the highest overlap with patients’ samples in the TAA expression profile.